Vivos Therapeutics, Inc.

NasdaqCM:VVOS Stock Report

Market Cap: US$7.5m

Vivos Therapeutics Future Growth

Future criteria checks 1/6

Vivos Therapeutics is forecast to grow earnings and revenue by 14.8% and 16.2% per annum respectively while EPS is expected to grow by 76.4% per annum.

Key information

14.8%

Earnings growth rate

76.4%

EPS growth rate

Healthcare earnings growth15.9%
Revenue growth rate16.2%
Future return on equityn/a
Analyst coverage

Low

Last updated08 Apr 2024

Recent future growth updates

Recent updates

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Apr 25
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Apr 18
Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Vivos Therapeutics again delays Q2 2022 results

Aug 23

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Jun 29

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

May 21
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

Vivos Therapeutics: First Take After The Broad Market Sell-Off

Mar 06

Vivos Therapeutics: Reimagining Sleep

Jul 30

Vivos Therapeutics prices $24M follow-on offering

May 07

Earnings and Revenue Growth Forecasts

NasdaqCM:VVOS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202519-10N/A-82
12/31/202416-11N/A-101
12/31/202314-14-13-12N/A
9/30/202315-15-13-12N/A
6/30/202315-19-16-15N/A
3/31/202316-20-18-17N/A
12/31/202216-24-21-20N/A
9/30/202216-25-22-21N/A
6/30/202217-25-20-19N/A
3/31/202217-22-20-18N/A
12/31/202117-20-18-16N/A
9/30/202116-24-17-15N/A
6/30/202115-21-14-12N/A
3/31/202113-19-9-9N/A
12/31/202013-18-6-6N/A
9/30/202013-9-4-4N/A
6/30/202013-11-4-4N/A
3/31/202012-12-4-4N/A
12/31/201911-12-6-5N/A
12/31/20184-9-7-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VVOS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VVOS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VVOS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VVOS's revenue (16.2% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: VVOS's revenue (16.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VVOS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.